A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteers

Trial Profile

A Phase II, open-label, randomised, dose-finding study to compare the efficacy (in terms of clearance of RhD-positive RBCs) and safety of LFB-R593, a monoclonal anti-RhD antibody, vs Rhophylac, a polyclonal anti-RhD immunoglobulin in healthy RhD negative volunteers

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2011

At a glance

  • Drugs Anti-D Rh0 immunoglobulin; Roledumab
  • Indications Haemolytic disease of newborn
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top